Cargando...

Access to orphan drugs despite poor quality of clinical evidence

AIM: We analysed the Belgian reimbursement decisions of orphan drugs as compared with those of innovative drugs for more common but equally severe diseases, with special emphasis on the quality of clinical evidence. METHODS: Using the National Health Insurance Agency administrative database, we eval...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dupont, Alain G, Van Wilder, Philippe B
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Science Inc 2011
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3080635/
https://ncbi.nlm.nih.gov/pubmed/21395641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03877.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!